<DOC>
	<DOCNO>NCT01067833</DOCNO>
	<brief_summary>To evaluate safety , efficacy , tolerability 3 dos K201 ( oral ) administer 28 day subject recent DC cardioversion sinus rhythm sustain symptomatic atrial fibrillation ( AF duration &gt; 3 day &lt; 6 month ) .</brief_summary>
	<brief_title>Phase 2 Study Oral K201 Prevention AF Recurrence</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Symptomatic AF ( sustain &gt; 3 day &lt; 6 month ) clinically indicated cardioversion ; Adequate anticoagulant therapy cardioversion accordance standard practice recommend ACC/AHA/ESC guideline local clinical practice ; Hemodynamically stable ( 90 mmHg &lt; systolic blood pressure &lt; 190 mmHg ) screen Day 1 ; Known prolonged QT syndrome QTc interval &gt; 0.500 sec screening ; familial long QT syndrome ; previous Torsade de Pointes ; ventricular fibrillation ; sustain ventricular tachycardia ( VT ) ; QRS &gt; 0.130 sec ; Previous episodes second thirddegree atrioventricular block ; Unsuccessful DC cardioversion attempt within 3 month ; prior ablation AF ; Persistent bradycardia ventricular rate 50 beats/min , sicksinus syndrome pacemaker ( include CRT , AICD ) ; Myocardial infarction ( MI ) , cardiac surgery , angioplasty , unstable angina acute coronary syndrome within 30 day prior entry study ; NYHA Class III Class IV heart failure ( HF ) screen admission , hospitalize HF previous 6 month ; Known concurrent temporary secondary cause AF ; Received Class I Class III antiarrhythmic agent ( include sotalol ) within 5 halflives randomization amiodarone dronedarone within 4 week ; Received treatment drug know prolong QT interval within 5 halflives .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>AF</keyword>
</DOC>